Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML
Sonia Jaramillo(Heidelberg University), Richard F. Schlenk(German Cancer Research Center), Johannes Krisam(University Hospital Heidelberg), Sabine Käyser(German Cancer Research Center), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Lukas Baumann(Statistics Austria), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Lucian Le Cornet(German Cancer Research Center), Olaf Hopfer(Goethe University Frankfurt), Dirk Niemann(Gemeinschaftsklinikum Mittelrhein), Thomas Geer, Markus Kratzmann(German Cancer Research Center), Andreas Rank(University Hospital Augsburg), Kerstin Schaefer-Eckart(Nuremberg Hospital), Arne Brecht(Deutsche Klinik für Diagnostik), Meinhard Kieser(Heidelberg University), Sebastian Buske(Clinical Research Center Kiel), Ralf Ulrich Trappe(Evangelisches Diakoniekrankenhaus), Lars Fransecky, Christoph Schliemann(University Hospital Münster), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Hubert Serve(Goethe University Frankfurt), Yousef Al-Fareh(Brüderkrankenhaus St. Josef Paderborn), Tim Sauer(Heidelberg University), Martina Crysandt(RWTH Aachen University), Martin Kaufmann(Robert Bosch Hospital), Martin Görner(Klinikum Bielefeld), Gerhard Held(Saarland University), Dirk Behringer(Augusta-Kranken-Anstalt), Jörg Schubert(Chamber of Deputies), Lino L. Teichmann(University Hospital Bonn)
Cited by 0
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k